MIDEAS

Across TCGA pan-cancer cohorts, MIDEAS mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MIDEAS data layer compared with 25 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MIDEAS mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MIDEAS expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and HNSC are the cancer types where MIDEAS mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.985	0.144	.008	18	view →
LUAD	OS	Median	All	0.999	0.921	.011	6	view →
HNSC	OS	Median	II,III,IV	1.000	0.955	.027	4	view →
LSCC	OS	Quartile	II,III,IV	0.932	0.623	.030	3	view →
PDAC	DFS	Median	II,III,IV	0.666	0.790	.035	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MIDEAS–CCRCC (DFS)

Open the CCRCC breakdown →